menu
    • menu
    [{"orgOrder":0,"company":"Immunofoco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell Therapy","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunofoco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunofoco \/ Undisclosed"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMC002","moa":"Claudin 18.2 (CLDN18.2)","graph1":"Oncology","graph2":"Phase I","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunofoco \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunofoco \/ Undisclosed"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Changhai Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Claudin 18.2 CAR-T Cell","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunofoco \/ Changhai Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Immunofoco \/ Changhai Hospital"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMC-001","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunofoco \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Immunofoco \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Immunofoco

    Menu

    Immunofoco

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immunofoco

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Immunofoco

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Study of AK104/AK112 with TT-00420 Tablet in Advanced Gastric Cancer Patients

                            Details : CAR-T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 05, 2025

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immunofoco

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Immunofoco

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMC-001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunofoco's IND for EpCAM CAR-T in Solid Tumors Approved by FDA and China CDE

                            Details : IMC001 is an EpCAM-targeting autologous CAR-T cell product evaluated for EpCAM-positive advanced gastrointestinal tumors, including gastric cancer and gastroesophageal junction adenocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 22, 2024

                            Lead Product(s) : IMC-001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immunofoco

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Immunofoco

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMC002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

                            Details : IMC002 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Digestive System Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 14, 2023

                            Lead Product(s) : IMC002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immunofoco

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Immunofoco

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Claudin 18.2 CAR-T Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Changhai Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

                            Details : Claudin 18.2 CAR-T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 25, 2022

                            Lead Product(s) : Claudin 18.2 CAR-T Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Changhai Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth